JL
Jason Lettmann
Chief Executive Officer

Jason Lettmann insider trades: Alx Oncology Holdings (ALXO) stock buys and sales

Chief Executive Officer, Alx Oncology Holdings Last trade Aug 17, 2026 25 Form 4 filings
$31K
Sold, last 12 months
2 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2016
2
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Jason reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Aug 17, 2026ALXO↓ Sell$4K
Mar 19, 2026ALXO↓ Sell$27K
Sep 17, 2025ALXO↑ Buy$99K
Aug 15, 2025ALXO↓ Sell$2K
Feb 19, 2025ALXO↓ Sell$2K
Mar 14, 2024ALXO↑ Buy$50K
Dec 13, 2021ALXO↓ Sell$8.9M
Dec 10, 2021ALXO↓ Sell$4.7M
Jul 21, 2020ALXO↑ Buy$7.6M
Oct 31, 2016RARX↑ Buy$5.1M
Oct 31, 2016RARX↓ Sell$4K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other ALXO insiders

Open-market trades in the last 12 months

About Jason Lettmann's insider trades

Jason Lettmann is Chief Executive Officer at Alx Oncology Holdings (ALXO). Since Oct 31, 2016, Jason has reported 4 open-market purchases worth $12.9M and 7 sales worth $13.6M on SEC Form 4. In the last 12 months: 2 sales ($31K).

Their filings also include grants and awards (13 filings), shares withheld for taxes (2 filings), conversions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ALXO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.